BRIB.F Stock Overview
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases primarily in China and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Brii Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.23 |
| 52 Week High | HK$0.59 |
| 52 Week Low | HK$0.23 |
| Beta | 1.77 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -61.73% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRIB.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.7% | 0.7% |
| 1Y | -61.7% | 2.7% | 23.9% |
Return vs Industry: BRIB.F underperformed the US Biotechs industry which returned 9.8% over the past year.
Return vs Market: BRIB.F underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| BRIB.F volatility | |
|---|---|
| BRIB.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BRIB.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BRIB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 133 | Zhi Hong | www.briibio.com |
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases primarily in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trail and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease.
Brii Biosciences Limited Fundamentals Summary
| BRIB.F fundamental statistics | |
|---|---|
| Market cap | US$88.63m |
| Earnings (TTM) | -US$24.18m |
| Revenue (TTM) | US$57.65m |
1.5x
P/S Ratio-3.7x
P/E RatioIs BRIB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRIB.F income statement (TTM) | |
|---|---|
| Revenue | CN¥416.75m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥416.75m |
| Other Expenses | CN¥591.58m |
| Earnings | -CN¥174.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Mar 25, 2024
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 100.00% |
| Net Profit Margin | -41.95% |
| Debt/Equity Ratio | 0% |
How did BRIB.F perform over the long term?
See historical performance and comparison